Bayer (FRA:BAYN) received a €70.00 ($81.40) target price from equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday. The firm currently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 2.52% from the company’s current price.
Several other research analysts have also recently issued reports on BAYN. Sanford C. Bernstein set a €89.00 ($103.49) price target on Bayer and gave the stock a “buy” rating in a research note on Monday, October 15th. Goldman Sachs Group set a €111.00 ($129.07) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday, October 17th. Jefferies Financial Group set a €77.00 ($89.53) price target on Bayer and gave the stock a “neutral” rating in a research note on Tuesday, October 23rd. equinet set a €96.00 ($111.63) price objective on Bayer and gave the company a “buy” rating in a report on Tuesday, October 23rd. Finally, UBS Group set a €122.00 ($141.86) price objective on Bayer and gave the company a “buy” rating in a report on Tuesday, October 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Bayer currently has an average rating of “Buy” and an average target price of €88.37 ($102.76).
FRA:BAYN opened at €68.28 ($79.40) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.